Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer

Human Pathology

Volumn 63, Issue , 2017, Pages 40-45

  Tokuda, Emi ^a   Horimoto, Yoshiya ^a   Arakawa, Atsushi ^a   Himuro, Takanori ^a   Senuma, Koji ^a   Nakai, Katsuya ^a   Saito, Mitsue ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Ki67; MIB 1; Neoadjuvant chemotherapy; Residual disease

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER TISSUE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEOADJUVANT CHEMOTHERAPY; RETROSPECTIVE STUDY; BIOPSY; BREAST NEOPLASMS; COMPARATIVE STUDY; JAPAN; MASTECTOMY; METABOLISM; METASTASIS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NEOADJUVANT THERAPY; PATHOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOKYO; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85017268662     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2017.02.005     Document Type: Article

References (22)

1. [1] Kaufmann, M., Minckwitz, G., Mamounas, E.P., et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19 (2011), 1508–1516.
2. [2] Horimoto, Y., Arakawa, A., Harada-Shoji, N., et al. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. Br J Cancer 112 (2015), 345–351.
3. [3] Sheri, A., Smith, I.E., Johnston, S.R., et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol 26 (2015), 75–80.
4. [4] Symmans, W.F., Peintinger, F., Hatzis, C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25 (2007), 4414–4422.
5. [5] Himuro, T., Horimoto, Y., Arakawa, A., et al. Activated caspase 3 expression in remnant disease after neoadjuvant chemotherapy may predict outcomes of breast cancer patients. Ann Surg Oncol, 1-7, 2016.
6. [6] Chang J. NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (NECTAR). US National Institutes of Health 2016. [Updated 12 September 2016. https://www.clinicaltrials.gov/ct2/show/NCT01931163].
7. [7] Toi, M., Lee, S.-J., Lee, E., et al. Abstract S1-07: a phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Res 76 (2016), S1–07.
8. [8] Millar, E.K.A., Graham, P.H., O'Toole, S.A., et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27 (2009), 4701–4708.
9. [9] Voduc, K.D., Cheang, M.C.U., Tyldesley, S., et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28 (2010), 1684–1691.
10. [10] Cheang, M.C.U., Chia, S.K., Voduc, D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101 (2009), 736–750.
11. [11] Jones, R.L., Salter, J., A'Hern, R., et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116 (2008), 53–68.
12. [12] von Minckwitz, G., Schmitt, W.D., Loibl, S., et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 19 (2013), 4521–4531.
13. [13] Horimoto, Y., Arakawa, A., Tanabe, M., et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer, 14, 2014, 550.
14. [14] Denkert, C., Loibl, S., Müller, B.M., et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 24 (2013), 2786–2793.
15. [15] Fasching, P.A., Heusinger, K., Haeberle, L., et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer, 11, 2011, 486.
16. [16] Assersohn, L., Salter, J., Powles, T.J., et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82 (2003), 113–123.
17. [17] Horii, R., Akiyama, F., Histological assessment of therapeutic response in breast cancer. Breast Cancer 23 (2016), 540–545.
18. [18] Kurosumi, M., Akashi-Tanaka, S., Akiyama, F., et al. Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer 15 (2008), 5–7.
19. [19] Wolmark, N., Wang, J., Mamounas, E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001 (2001), 96–102.
20. [20] Bossuyt, V., Provenzano, E., Symmans, W.F., et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 26 (2015), 1280–1291.
21. [21] Provenzano, E., Bossuyt, V., Viale, G., et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28 (2015), 1185–1201.
22. [22] Regan, M.M., Pagani, O., Francis, P.A., et al. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 154 (2015), 275–286.